LIV-1 CAR-T / CRISPR Therap - LARVOL DELTA

Allogeneic CAR T cells targeting Liv-1 for breast cancer (SITC 2023) - "Liv1 is being explored clinically as a target via an antibody drug conjugate (ADC: Ladiratuzumab vedotin) which has shown encouraging safety and anti tumor data. Its specific expression in breast cancer, as opposed to other tissues, reduces the risk of off-target toxicity. We have demonstrated that anti-Liv1 CAR T cells can be produced with potent in vitro and in vivo CAR T cell activity against multiple breast cancer cell lines."

CAR T-Cell Therapy • IO biomarker • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) - "CRISPR Therapeutics...announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023."

Preclinical • Breast Cancer • Hepatocellular Cancer